Allelic variation at the interleukin 1β gene is associated with decreased bone mass in patients with inflammatory bowel diseases

A Nemetz, M Tóth, M A García-González, T Zágoni, J Fehér, A S Peña, Z Tulassay

Abstract

Background—Interleukin 1β (IL-1β) and its natural antagonist have been implicated in the pathogenesis of inflammatory bowel disease (IBD). Both cytokines influence bone formation. IL-1β stimulates osteoclast activity while interleukin 1 receptor antagonist (IL-1ra) enhances bone formation.

Aims—To determine whether the decreased bone mass in IBD is related to gene polymorphisms coding for IL-1β and IL-1ra, and thus identify patients with an increased risk.

Methods—Bone mineral densitometry was performed at the femoral neck, lumbar spine, and the distal third of the radius in 75 IBD patients (34 men/41 women; 40.3 (1.6) years) and in 58 healthy controls (HC; 28 men/30 women; 32.4 (1.2) years). Values were correlated with the TagI and AvaI gene polymorphisms in the IL1B and the variable number of tandem repeats gene polymorphism in the IL1RN gene.

Results—In IBD patients, but not in HC, carriers of allele 2 at the AvaI gene polymorphism (IL1B-511*2) had significantly lower Z scores at the lumbar spine (−0.82 (0.13) v −0.29 (0.21) p=0.03) and the femoral neck (−0.59 (0.14) v 0.15 (0.19); p=0.003) than non-carriers. These patients also had a higher risk for osteopenia or osteoporosis at the femoral neck (odds ratio 3.63 (95% confidence interval 0.95–13.93)). No association was found between bone mass and the other gene polymorphisms analysed in IBD patients or in HC.

Conclusions—Our results suggest that genetic variability may be a major determinant of bone loss in IBD. Carriers of IL1B-511*2, who are hypersecretors of IL-1β, have a higher risk of presenting with low bone mass in IBD. Screening for this allele may contribute to determination of the risk of bone loss at the time of disease onset.

(Gut 2001;49:644–649)

Keywords: inflammatory bowel diseases; ulcerative colitis; Crohn’s disease; osteoporosis; bone density; genetic polymorphisms; interleukin 1

Inflammatory bowel diseases (IBD)—Crohn’s disease (CD) and ulcerative colitis (UC)—are associated with decreased bone mineral density and an increased prevalence of osteoporosis.1

The pathogenesis of this increased bone loss is not yet fully understood. Risk factors for reduced bone mass in patients with IBD may include the causes of idiopathic osteoporosis, as well as specific factors related to the inflammatory process.

Cytokines influence bone remodelling by regulating differentiation as well as the activity of osteoclasts and osteoblasts. A key proinflammatory cytokine cytokine interleukin 1β (IL-1β) stimulates osteoclast development and activity,7 and was found to decrease bone collagen and non-collagen protein synthesis.5 The naturally occurring antagonist of IL-1β, the interleukin 1 receptor antagonist (IL-1ra), stimulates bone formation and decreases the number of osteoclasts on the endocortical surfaces.7 Moreover, greater spinal bone loss was observed among premenopausal women with higher stimulated production of IL-1β.3 Spontaneous secretion of IL-1 by cultured peripheral blood mononuclear cells was significantly higher in osteoporotic patients compared with healthy subjects.5

As in high turnover osteoporosis, enhanced circulating levels of IL-1β have been reported in patients with IBD.7 The altered production and mucosal ratio of IL-1β and IL-1ra is strongly suggested to be a pathogenic factor in IBD.8,9 Increased production of IL-1β was implicated as a possible reason for increased bone loss in IBD.11

Family, twin, and epidemiological studies indicate that genetic factors play an important role in determining bone mass.10–14 Assessment of bone turnover markers suggests a genetic influence in the regulation of bone metabolism.15 Although there is evidence that the genotype influences both peak bone mass and the rate of bone loss, no overall susceptibility genes for osteoporosis have yet been identified.16–21 The inconsistencies of candidate gene studies are due to the multifactorial regulation of bone mineral density: a polygenic predisposition is modified by environmental and lifestyle factors.

As members of the IL-1 family play an important role in the regulation of bone formation, genes involved in the control of their activity provide other candidate loci for susceptibility to increased bone loss. Indeed, allelic variations at the IL-1 receptor antagonist gene
Table 1  Clinical characteristics of inflammatory bowel disease (IBD) patients according to their carriercship of allele IL1B-511<sup>+</sup>2

<table>
<thead>
<tr>
<th>Non-carriers of allele</th>
<th>Carriers of allele</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL1B-511&lt;sup&gt;+&lt;/sup&gt;2</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Age (y)</td>
<td>40.6 (2.5)</td>
<td>40.1 (2.0)</td>
</tr>
<tr>
<td>Sex (F/M)</td>
<td>11/13</td>
<td>29/22</td>
</tr>
<tr>
<td>Disease type (UC/CD)</td>
<td>12/12</td>
<td>27/24</td>
</tr>
<tr>
<td>Disease duration (y)</td>
<td>11.0 (1.6)</td>
<td>7.5 (1.6)</td>
</tr>
<tr>
<td>Body mass index (kg/m&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>24.04 (0.87)</td>
<td>22.57 (0.47)</td>
</tr>
<tr>
<td>Ever received systemic steroids (yes/no)</td>
<td>17/7</td>
<td>37/14</td>
</tr>
<tr>
<td>Body mass index (kg/m&lt;sup&gt;2&lt;/sup&gt;)</td>
<td>24.04 (0.87)</td>
<td>22.57 (0.47)</td>
</tr>
<tr>
<td>UC: total colitis (n)</td>
<td>1 3</td>
<td>2 3</td>
</tr>
<tr>
<td>UC: proctitis (n)</td>
<td>0 3</td>
<td>0 3</td>
</tr>
<tr>
<td>UC: left sided disease (n)</td>
<td>6 17</td>
<td>6 17</td>
</tr>
<tr>
<td>UC: total colitis (n)</td>
<td>6 7</td>
<td>6 7</td>
</tr>
</tbody>
</table>

Values are mean (SE).

UC, ulcerative colitis; CD, Crohn’s disease.

Materials and methods

Patients

Seventy-five patients with IBD, 39 patients with UC (17 men/22 women; aged 43 (2.6) years) and 36 with CD (17 men/19 women; aged 35 (1.8) years), were included in the study. A group of 58 healthy individuals (HC) (28 men/30 women; aged 32 (1.2) years) served as control subjects. The sample size was made up from those unrelated individuals of Hungarian origin of the invited 100 IBD patients and 120 HC. Diagnosis and extent of IBD were determined by conventional clinical, endoscopic/radiological, and histopathological criteria.28 One CD patient had a childhood disease onset; hemicolectomy had been performed on seven CD and one UC patient while ileal resection had been carried out in four cases. Categories for classification of CD patients were set according to the Vienna classification:27 seven had terminal ileal, six colonic, and 1 ileocolic disease, while four patients had additional upper gastrointestinal disease location. Z scores for patients with a location including the small bowel were not different from the rest of the IBD group. No patient received hormone replacement therapy or any bone active drugs other than corticosteroids. Sixteen IBD patients were taking over the counter multivitamin/mineral supplements in regular daily doses (table 1). The ethics committees of the participant universities approved the study. Informed consent was obtained from all patients.

DNA isolation, polymorphism typing

Genomic DNA was extracted from EDTA anticoagulated peripheral blood according to the standard protease-K digestion and phenol-chloroform extraction method. Two biallelic restriction fragment length polymorphisms (RFLP) at positions −511 and +3953 of the IL1B gene and a penta-allelic VNTR polymorphism in the IL1RN gene were determined according to previously described methods.28,30–32 Summarised conditions are given in table 2.

Bone mineral densitometry

Bone mineral densitometry was performed by dual x-ray absorptiometry at the left femoral neck, lumbar spine (L2–L4), and the distal third of the non-dominant radius using a Hologic QDR 4500C instrument (Hologic Inc., Waltham, Massachusetts, USA). The longitudinal precision of measurements on a Hologic spine phantom has a coefficient of variation of 0.35%. Data were obtained for absolute areal bone density (g/cm<sup>2</sup>) and were also expressed as the number of SDs below or above the age and sex standardised average (Z scores). According to the recommendations of the WHO, T score values were used (the number

Table 2  Reaction conditions used for detection of interleukin 1 (IL1) gene family polymorphisms

<table>
<thead>
<tr>
<th>Position</th>
<th>Primers (5’ to 3’)</th>
<th>Annealing temp (°C)</th>
<th>Type of polymorphism</th>
<th>Alleles</th>
</tr>
</thead>
<tbody>
<tr>
<td>IL1B-511</td>
<td>Sense: TTGCAATTCGATCTGTACGTCTTTGCTCCTCCACTT</td>
<td>55</td>
<td>Aval RFLP</td>
<td>1=Digested fragment (190 bp and 115 bp)</td>
</tr>
<tr>
<td></td>
<td>Antisense: GCTTGATCTTCACTGTTGATCGCTCTCTCCTTCCTTGCAC</td>
<td></td>
<td></td>
<td>2=Intact fragment (305 bp)</td>
</tr>
<tr>
<td>IL1B-3954</td>
<td>Sense: GGTTGATCTGACATTTGGAGCC</td>
<td>55</td>
<td>TaqI RFLP</td>
<td>1=Digested fragment (135 bp and 114 bp)</td>
</tr>
<tr>
<td></td>
<td>Antisense: ATTCGATCTGATATCGGACATCTGCAGGACA</td>
<td></td>
<td></td>
<td>2=Intact fragment (249 bp)</td>
</tr>
<tr>
<td>IL1RN 2nd intron</td>
<td>Sense: CTCTGATCTGATGAGCTAGA</td>
<td>60</td>
<td>VNTR</td>
<td>1=4 repeats of the 86 bp region (410 bp)</td>
</tr>
<tr>
<td></td>
<td>Antisense: CCGTTGATCTGACAGTAA</td>
<td></td>
<td></td>
<td>2=2 repeats (240 bp)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>3=5 repeats (500 bp)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>4=3 repeats (325 bp)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5=6 repeats (595 bp)</td>
</tr>
</tbody>
</table>

RFLP, restriction fragment length polymorphism; VNTR, variable number of tandem repeats.
Table 3  Bone mass (mean (SE)) in carriers and non-carriers of allele IL1B-511*2 among patients with inflammatory bowel disease

<table>
<thead>
<tr>
<th>Bone mineral density (g/cm²)</th>
<th>Non-carriers of allele IL1B-511*2 (n=24)</th>
<th>Carriers of allele IL1B-511*2 (n=53)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lumbar spine (L2-L4)</td>
<td>1.03 (0.03)</td>
<td>0.96 (0.02)</td>
<td>0.03</td>
</tr>
<tr>
<td>Femoral neck</td>
<td>0.85 (0.03)</td>
<td>0.76 (0.02)</td>
<td>0.007</td>
</tr>
<tr>
<td>Radius distal 1/3</td>
<td>0.72 (0.03)</td>
<td>0.70 (0.02)</td>
<td>NS</td>
</tr>
<tr>
<td>Z scores</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lumbar spine (L2-L4)</td>
<td>−0.29 (0.21)</td>
<td>−0.82 (0.13)</td>
<td>0.03</td>
</tr>
<tr>
<td>Femoral neck</td>
<td>+0.15 (0.19)</td>
<td>−0.59 (0.14)</td>
<td>0.003</td>
</tr>
<tr>
<td>Radius distal 1/3</td>
<td>−0.45 (0.20)</td>
<td>−0.80 (0.17)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Table 4  Z scores (mean (SEM)) of carriers and non-carriers of allele IL1B+3954 and the IL1RN variable number of tandem repeat (VNTR) polymorphic sites in inflammatory bowel disease patients

<table>
<thead>
<tr>
<th>IL1B TaqI site</th>
<th>Non-carriers of allele 2 (n=53)</th>
<th>Carriers of allele 2 (n=36)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lumbar spine (L2-L4)</td>
<td>−0.74 (0.15)</td>
<td>−0.46 (0.17)</td>
<td>NS</td>
</tr>
<tr>
<td>Femoral neck</td>
<td>−0.38 (0.15)</td>
<td>−0.29 (0.19)</td>
<td>NS</td>
</tr>
<tr>
<td>Radius distal</td>
<td>−0.77 (0.16)</td>
<td>−0.52 (0.20)</td>
<td>NS</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>IL1RN VNTR site</th>
<th>Non-carriers of allele 2 (n=37)</th>
<th>Carriers of allele 2 (n=36)</th>
<th>p Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Lumbar spine (L2-L4)</td>
<td>−0.64 (0.17)</td>
<td>−0.67 (0.15)</td>
<td>NS</td>
</tr>
<tr>
<td>Femoral neck</td>
<td>−0.26 (0.15)</td>
<td>−0.43 (0.18)</td>
<td>NS</td>
</tr>
<tr>
<td>Radius distal</td>
<td>−0.55 (0.17)</td>
<td>−0.81 (0.19)</td>
<td>NS</td>
</tr>
</tbody>
</table>

Results
There were no significant differences in Z scores between patients with CD and UC (lumbar spine −0.64 (0.18) v −0.64 (0.17); femoral neck −0.46 (0.16) v −0.38 (0.16); radius −0.85 (0.09) v −0.62 (0.19)) and therefore we analysed IBD patients as one group. IL1B and IL1RN genotype frequencies in HC and IBD patients were similar to those reported previously.27 33

In IBD patients, the MANOVA test showed significant differences between bone mineral density (BMD) values of carriers and non-carriers of allele 2 at the AvaI polymorphic site (IL1B-511*2). Carriers of allele IL1B-511*2 had significantly lower BMD values at the lumbar spine (p=0.03) and at the femoral neck (p=0.007) while at the radius the difference did not reach statistical significance (overall MANOVA p=0.048) (table 3). These findings were also present when sex and age standardised Z scores were compared (lumbar spine p=0.03; femoral neck p=0.003; overall MANOVA p=0.03) (table 3). The relative risk of low bone mass (osteopenia or osteoporosis) at the femoral neck was also higher for carriers of allele IL1B-511*2. Among the 23 patients with low bone mass detected at this site, only three were non-carriers of the IL1B-511*2 allele (OR 3.65; 95% CI 0.95–13.93). However, this phenomenon could not be observed at the lumbar spine (OR 1.47; 95% CI 0.46–4.68) or at the radius (OR 1.5; 95% CI 0.36–6.26).

No association was found at any of these locations between the number of IL1B-511*2 alleles present in an individual and the severity of bone loss (Z scores of heterozygotes v homozygotes for allele IL1B-511*2: lumbar spine −0.85 (0.15) v −0.76 (0.28); femoral neck −0.61 (0.16) v −0.54 (0.26); radius −0.86 (0.19) v −0.61 (0.37)).

There were no significant differences between the groups of carriers and non-carriers of allele IL1B-511*2 in terms of age, age at disease onset, body mass index, ratio of patients with CD and UC, or occurrence of corticosteroid therapy in their anamnesis (table 1). Similarly, we found no significant differences in male/female ratios between carriers and non-carriers of the IL1B-511*2 allele. However, when analysing male and female IBD patients separately, in men there was a significant association between lower Z scores and the presence of allele IL1B-511*2 both at the lumbar spine (p=0.01) and at the femoral neck (p=0.038) while in women there was no association at the lumbar spine but only at the femoral neck. Moreover, after correction for multiple comparisons, the difference found at the femoral neck in women was no longer significant.

There was no association in IBD patients between Z scores and the presence of allele 2 at the VNTR gene polymorphism in the IL1RN gene (IL1RN*2) or the presence of allele 2 at the TaqI gene polymorphism in the IL1B (table 4). Similarly, in HC, no association was found between bone mineral density and carriership of allele 2 at any of the investigated polymorphic sites (carriers v non-carriers of allele IL1B-511*2: lumbar spine 1.00 (0.02) v 1.03 (0.02); femoral neck 0.84 (0.03) v 0.89 (0.03); radius 0.71 (0.01) v 0.71 (0.02)). No significant association was found between the −511 and +3954 gene polymorphisms in our HC while the frequency of the IL1B-511*2 allele was higher in the IBD than in the control population (0.44% v 0.31%).

Discussion
The pathogenesis of reduced bone mineral density in IBD is not fully understood. Patients...
with corticosteroid treatment, small bowel disease or intestinal resection, or a longstanding or extensive disease have been suggested to be at a higher risk of bone loss. However, there is no consensus in different studies as to which factor is significant in the evolution of decreased bone mass.\textsuperscript{11} 34–36 Moreover, a high prevalence of low bone mineral density was found in patients with newly diagnosed CD and among IBD patients with a low risk of metabolic bone disease.\textsuperscript{11} These results raise the possibility that other factors, present already before the onset of the disease, contribute to the low bone mass and enhanced bone loss in IBD patients.

In this study we have found that the presence of the \textit{IL1B-511}*2 allele was associated with significantly lower Z scores and a higher risk of osteopenia and osteoporosis in IBD patients. This allele has previously been related to increased in vitro production of IL-1\(\beta\) by mononuclear cells.\textsuperscript{25} Elevated levels of IL-1\(\beta\) and/or an imbalance between IL-1\(\beta\) and IL-1ra production could result in increased bone loss. IL-1\(\beta\) was described as enhancing bone resorption by increasing the number and activity of osteoclasts while having no effect on bone formation. Animal studies have also suggested that IL-1ra treatment decreased the activity and number of osteoclasts on endocortical surfaces.\textsuperscript{7} Previous studies in IBD have shown increased bone resorption rates while levels of bone formation markers were similar to those of healthy individuals.\textsuperscript{11} 37 Thus the lower bone mass of IBD patients can be partly explained by elevated IL-1\(\beta\) levels and increased IL-1\(\beta\)/IL-1ra ratio observed in these diseases.

Similar to our findings, the study of Keen et al\textsuperscript{22} suggested the importance of \textit{IL1} genes in determining bone mass. In their population of early postmenopausal women, an association was found between the expression of the \textit{IL1RN}*2 allele and reduced bone loss at the spine. This allele has previously been related to increased production of IL-1ra.\textsuperscript{24} Thus in patients carrying the \textit{IL1RN}*2 allele, IL-1\(\beta\) could induce a smaller biological response when competing for binding to IL-1 receptors. However, in the study of Keen et al, an association was only seen between the \textit{IL1RN} polymorphisms and the rate of bone loss, not with actual Z scores, whereas in the present study the \textit{IL1B-511} polymorphism was found to influence bone mass in IBD. These differences may be due to the different ages of the study groups, to the presence of IBD, or to the different end point of the studies.

As there is evidence that \textit{IL1B} genotype influences the course of IBD,\textsuperscript{27 32} these results suggest that the inflammatory process alters regulation of bone resorption, as previously described. Our earlier studies found a higher frequency of the \textit{IL1B-511}*2 allele among UC patients whose leading symptom was diarrhoea than among those presenting with spontaneous rectal bleeding.\textsuperscript{33} Therefore we propose that a specific disease course related to or manifested as alterations in the nature of intestinal absorption—such as an accelerated passage or greatly increased intestinal permeability causing dysregulated absorption—may be associated with a higher extent of bone loss. For instance, a recently published study has found that intestinal infection is also a useful predictor of relapse in patients with CD and faecal calprotectin in both CD and UC.\textsuperscript{38}

Genetic variations in the \textit{IL1B} gene have been linked to several other chronic multifactorial diseases such as adult periodontal disease,\textsuperscript{39–40} insulin dependent diabetes mellitus,\textsuperscript{41} and schizophrenia.\textsuperscript{40} Thus we could hypothesise that the \textit{IL1B} gene, by controlling the production of IL-1\(\beta\), influences the severity and course of different diseases. Additional genetic, environmental, and lifestyle factors or infections would determine if any of these diseases develops. Although we could not fully confirm the lack of association between the \textit{IL1B-511} polymorphism and BMD in the general population because of the smaller number of individuals in the HC group in this study, our results suggest that the underlying bowel disease resulting in long term upregulated IL-1\(\beta\) production may be necessary to induce bone loss. A recently published study has also shown an example of interaction of the IL-1 gene cluster and additional host factors towards progression to disease. A higher frequency of the \textit{IL1B-511}*2 allele among \textit{Helicobacter pylori} infected relatives of gastric cancer patients with low acid secretion was found but not among those not infected with \textit{H pylori}.\textsuperscript{43} Moreover, the study also found almost total linkage disequilibrium between the \textit{IL1B} polymorphisms at positions -511 and -31, this latter being a TATA box polymorphism markedly affecting DNA-protein interactions in vitro.

Our results suggest that sex may be an important modifying factor in IBD. Male sex was reported to be an independent risk factor for osteoporosis in earlier studies.\textsuperscript{35} It is currently accepted that oestrogen plays a key role in the regulation of bone turnover in both sexes.\textsuperscript{35–36} Recent studies have demonstrated that oestrogens reduce expression of signalling type IL-1 receptor (IL-1RI) in osteoclasts while it increases expression of decoy type IL-1 receptor (IL-1RII), together decreasing IL-1 bioresponsiveness of these cells.\textsuperscript{44–46} This regulatory effect of oestrogen was similar in cells from both male and female donors. In contrast, steady state IL-1RII/IL-1RI ratios in osteoclast-like cells of men were found to be lower than those of early postmenopausal women, suggesting that similar IL-1\(\beta\) levels may have a stronger bone resorptive effect in men than in women.

In this study the association between the genotype of the AvaI gene polymorphism and bone mass in IBD patients was strongest at the femoral neck. This is in agreement with other studies reporting a greater prevalence of reduced hip BMD in IBD compared with the frequency of vertebral or forearm osteoporosis.\textsuperscript{35–36} It was confirmed that the pathogenesis of bone loss in IBD is different from the clearly steroid induced bone disease, which affects vertebrae to a greater extent.
Although several general and IBD related osteoporosis risk factors are suspected to contribute to the increased bone loss in IBD, results on the extent of their roles are controversial and are not applicable to predicting osteopenia in the long term at the time of diagnosis of the disease. We have shown that carriers of the IL1B-511*2 allele have a higher risk of presenting with low bone mass in IBD. These results may extend our knowledge regarding the pathogenesis of low bone mass in IBD patients. Furthermore, screening for the Afl gene polymorphism in the IL1B gene could contribute towards determining the risk of bone loss in IBD patients at the time of diagnosis and treatment. Early identification of patients at high risk of osteoporosis could help to set up more effective "tailor made" therapy. Our results, together with the recent study in Gastroenterology, suggest that genetic variability may be a major determinant of bone loss in IBD.

We would like to acknowledge the financial support of Astellas, the Netherlands, to MA García-González. Nemetz was supported by the "Vrije Universiteit Vrouwen Fonds". We thank E Dinys and P Vargha for help in performing the statistical analysis. Preliminary work was presented in the "Genetics of IBD" thematic session at the 7th UEGW meeting in Rome, and the abstract has been published in Gut 1999;45(suppl 8):A15.

18 Langdale BL, Knudsen JY, Jensen HK, et al. A sequence variation: 713–866C; in the transforming growth factor-β1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone 1997;20:289–94.
42 Riggs BL, Khosla S, Melton LJ, 3rd. A unitary model for involutional osteoporosis; estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women.


---

**7th European Forum on Quality Improvement in Health Care**

21–23 March 2002

Edinburgh, Scotland

We are delighted to announce this forthcoming conference in Edinburgh. Delegate enquiries are welcome.

The themes of the Forum are:

- Leadership, culture change, and change management
- Achieving radical improvement by redesigning care
- Health policy for lasting improvement in health care systems
- Patient safety
- Measurement for improvement, learning, and accountability
- Partnership with patients
- Professional quality: the foundation for improvement
- Continuous improvement in education and training
- People and improvement.

Presented to you by the BMJ Publishing Group (London, UK) and Institute for Healthcare Improvement (Boston, USA). For more information contact: quality@bma.org.uk or look at the website www.quality.bmjpg.com. Tel: +44 (0)20 7383 6409; fax: +44 (0)20 7373 6869.